Skip to content
10-Q

Quarterly Report

ADC Therapeutics SA ADCT

0001628280-25-025481

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 99.18M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $194.7M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $250.87M
Current Liabilities Q1 2025 · Mar 31, 2025 $57.79M
Current Liabilities Q1 2025 · Dec 31, 2024 $80.47M
Total Liabilities Q1 2025 · Mar 31, 2025 $510.76M
Total Liabilities Q1 2025 · Dec 31, 2024 $524.62M
Current Assets Q1 2025 · Mar 31, 2025 $257.99M
Current Assets Q1 2025 · Dec 31, 2024 $307.39M
Total Assets Q1 2025 · Mar 31, 2025 $272.54M
Total Assets Q1 2025 · Dec 31, 2024 $321.98M
Shares Diluted Q1 2025 · Mar 31, 2024 82.55M sh
Capex Q1 2025 · Mar 31, 2024 $531K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$44.1M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$194.45M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$148.25M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.56
Eps Basic Q1 2025 · Mar 31, 2024 −$0.56
Sga Expense Q1 2025 · Mar 31, 2024 $12.03M
Rd Expense Q1 2025 · Mar 31, 2024 $25.74M
Net Income Q1 2025 · Mar 31, 2024 −$46.61M
Operating Income Q1 2025 · Mar 31, 2024 −$33.61M
Revenue Q1 2025 · Mar 31, 2024 $17.85M